X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75%…
Sky City Acoma Casino Hotel Selects QCI Resorts™, the Unified Intelligence Platform for Resorts